1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Regulation

FDA Tests WEN Conditioner’s MI/MCI Content In Pursuit Of Hair-Loss Answers

 
• By Ryan Nelson

The MI/MCI preservative combination is a suspect being explored by FDA as part of its investigation into reports of hair loss and other adverse effects linked to WEN Cleansing Conditioners. The agency discusses testing it undertook to quantitate the WEN products’ MI/MCI content in a response to concerns raised by Democratic Congressman Frank Pallone of New Jersey.

Research and anecdotal evidence connecting contact dermatitis of the scalp to hair loss may have factored in FDA’s early focus on the MI/MCI preservative combination as it investigates the safety of WEN Cleansing Conditioners.

The agency swapped letters in March with Rep. Frank Pallone, D-N.J

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Regulation

More from Policy & Regulation

US Fragrance Firms Should Identify Domestic, Non-Tariff Sources Now – Fragrance House CEO

Firms in the US facing tariff costs should identify US-based, non-tariff sources and lobby local government officials and DC when foreign-sourced ingredients cannot be substituted in the US.

Cosmetics Consortium Shares Studies With FDA To Build Confidence In Animal Testing Alternatives

 
• By Lauren Nardella

By guiding regulators through case studies and mock dossier examples of how to utilize new approach methodologies, the International Collaboration on Cosmetics Safety hopes to counter hesitations in replacing animal tests.

Stakeholders Hope US FDA’s Proposed Animal Test Phase-Out For Drugs Will Extend To OTCs, Cosmetics

 
• By Eileen Francis and Lauren Nardella

The US Food and Drug Administration has released a roadmap to adopt new approach methodologies in lieu of animal testing for monoclonal antibody therapies and other drugs, which may include OTC drugs though the proposal does not specifically include cosmetics.